Pfizer plans to pull leukemia drug Mylotarg from U.S. market

06/21/2010 | Reuters

Pfizer will voluntarily take Mylotarg off the U.S. market Oct. 15 after the injectable drug failed to show efficacy during a study when given in combination with chemotherapy to patients with acute myeloid leukemia. The decision follows the FDA's recommendation to withdraw the product because of safety concerns and lack of clinical benefit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN